期刊
THERAPEUTIC ADVANCES IN CHRONIC DISEASE
卷 4, 期 3, 页码 119-141出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040622313478646
关键词
aetiology; autoimmune hepatitis; autoimmune liver disease; primary biliary cirrhosis; primary sclerosing cholangitis; pathogenesis; treatment
资金
- Wellcome Trust Clinical Research Fellowship Program
Autoimmune liver disease spans three predominant processes, from the interface hepatitis of autoimmune hepatitis to the lymphocytic cholangitis of primary biliary cirrhosis, and finally the obstructive fibrosing sclerotic cholangiopathy of primary sclerosing cholangitis. Although all autoimmune in origin, they differ in their epidemiology, presentation and response to immunosuppressive therapy and bile acid based treatments. With an ongoing better appreciation of disease aetiology and pathogenesis, treatment is set ultimately to become more rational. We provide an overview of current and future therapies for patients with autoimmune liver disease, with an emphasis placed on some of the evidence that drives current practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据